



Frontiers in Biotechnology

Management 274a01, MIMG C133/C233

Winter 2007, Tuesdays & Thursdays 1:00-2:30 pm (first class 1/9/07)

Gold Hall B301, UCLA Anderson School

Prof Martin Greenberger mg@ucla.edu, *Prof Fred Fox* fredfox@microbio.ucla.edu

Sixteen distinguished guests:

1. **Richard Hamilton, CEO, Ceres, Inc.** *agricultural biotechnology*
2. **Wendell Wierenga, EVP R&D, Neurocrine Biosciences,** *drug discovery*
3. **Thomas Okarma, President & CEO, Geron Corp,** *embryonic stem cells*
4. **Mark Edwards, Managing Director, Recombinant Capital,** *funding strategy*
5. **Leslie Raffel MD, Cedars-Sinai, UCLA Pediatrics,** *genetics, stem cells & ethics*
6. **Marc Hedrick MD, President, Cytori Therapeutics,** *adult stem cell therapies*
7. **Larry Souza, Former Amgen Director of Research,** *evolution of biotech*
8. **Frank Litvack MD, CEO, Conor Medsystems,** *cardiovascular stent devices*
9. **Aya Jakobovits, SVP & CSO, Agensys, Inc.** *attacking cancer with antibodies*
10. **Joel Huizenga, CEO, No Lie MRI,** *diagnostic & forensic applications of fMRI*
11. **Richard Warburg, Attorney, Foley & Lardner LLP,** *intellectual property*
12. **Basil Dahiyat, CEO, Xencor, Inc.,** *computationally-designed proteins*
13. **Gary Wilcox, EVP of Operations, ICOS Corp,** *from partnership to merger*
14. **Jack Newman, VP Res, Amyris Biotechnologies,** *platforms: malaria drugs & biofuels*
15. **Patrick Soon-Shiong, Founder, CEO, APP,** *nano drug delivery systems for cancer*
16. **Steve Kaldor, President, Syrrx,** *exploiting structural proteomics in drug discovery*